source
- FDA approves Rasonque, first therapy targeting genetic cause of advanced pancreatic cancerThe U.S. Food and Drug Administration has granted approval to Rasonque, a drug from Revolution Medicines, for patients with advanced pancreatic cancer. The medicine, whose generic name is daraxonra…
- FDA approves Revolution Medicines' daraxonrasib for second-line pancreatic cancerThe U.S. Food and Drug Administration announced approval of Revolution Medicines' drug daraxonrasib for patients with pancreatic cancer who have already received prior therapy. The approval marks…